Recently, AstraZeneca and Merck & Co., Inc. announced updated results from the OlympiA Phase III trial of Lynparza (olaparib) in early breast cancer at the San Antonio Breast Cancer Symposium (SABCS). Olaparib is the first and only PARP inhibitor to improve survival in this setting.
Advertisement
Despite decades of decline, "lung cancer continues to dwarf other cancers in the number of deaths," officials said.
The new indication is for use of the alkylating agent with fludarabine in a preparatory combination for allogeneic HSCT.
Previous data pointed to the benefit of adjuvant immunotherapy for patients with HCC through the use of CIK cells.
Previously presented results of the trial showed favorable PFS rates in the m-FOLFOXIRI and cetuximab arm.
Dr. Ajay Singh and others pay tribute to Dr. Barry Brenner, a leading nephrologist who passed away in August 2024.
Dr. Lieu details practice-changing studies from ASCO GI 2025, including CheckMate-9DW, CheckMate 8HW, and BREAKWATER.
The combination of EVE/LAN can significantly prolong PFS in patients with well-differentiated grade 1/2 GEP-NETs.
Dapsone demonstrates efficacy and acceptable safety with low costs as treatment for pediatric ITP.
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
Previous data pointed to the benefit of adjuvant immunotherapy for patients with HCC through the use of CIK cells.
Previously presented results of the trial showed favorable PFS rates in the m-FOLFOXIRI and cetuximab arm.
Dr. Lieu details practice-changing studies from ASCO GI 2025, including CheckMate-9DW, CheckMate 8HW, and BREAKWATER.
The combination of EVE/LAN can significantly prolong PFS in patients with well-differentiated grade 1/2 GEP-NETs.
ASPEN-06 analyzed the CD47 myeloid checkpoint inhibitor ALX148 in patients with HER2-overexpressing gastric cancer.
In EMERALD-1, investigators analyzed the combination of durvalumab plus bevacizumab and TACE versus placebo with TACE.
The Latest From Heme Today
The new indication is for use of the alkylating agent with fludarabine in a preparatory combination for allogeneic HSCT.
Dapsone demonstrates efficacy and acceptable safety with low costs as treatment for pediatric ITP.
Two therapies being developed for EBV-positive PTLD, non-Hodgkin lymphoma, and systemic lupus erythematosus are affected.
Preliminary efficacy and safety findings from a multicenter, open-label, phase Ib/II prospective study have been encouraging.
Gut microbiota modulates bleeding risk in pediatric patients with immune thrombocytopenia.
ASH's efforts pertain to professional recruitment as well as to address unique medical issues in patient populations.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.